The Light at the End of the Tunnel-Second Generation HPMA Conjugates for Cancer Treatment.

about

The Light at the End of the Tunnel-Second Generation HPMA Conjugates for Cancer Treatment.

Item

http://www.wikidata.org/entity/Q48558433

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

The Light at the End of the Tu ...... njugates for Cancer Treatment.

@en

The Light at the End of the Tu ...... njugates for Cancer Treatment.

@nl

type

Item

label

The Light at the End of the Tu ...... njugates for Cancer Treatment.

@en

The Light at the End of the Tu ...... njugates for Cancer Treatment.

@nl

prefLabel

The Light at the End of the Tu ...... njugates for Cancer Treatment.

@en

The Light at the End of the Tu ...... njugates for Cancer Treatment.

@nl

P1476

The Light at the End of the Tu ...... njugates for Cancer Treatment.

@en

P2093

Jindřich Kopeček

http://www.w3.org/2001/XMLSchema#string

Jiyuan Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Polymer-drug conjugates: origins, progress to date and future directions

Preclinical mouse cancer models: a maze of opportunities and challenges.

Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee

Direct, controlled synthesis of the nonimmunogenic, hydrophilic polymer, poly(N-(2-hydroxypropyl)methacrylamide) via RAFT in aqueous media.

Combination chemotherapy and photodynamic therapy of targetable N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin/mesochlorin e(6)-OV-TL 16 antibody immunoconjugates.

Biodistribution and antitumour efficacy of long-circulating N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in nude mice.

Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)

HPMA copolymers: origins, early developments, present, and future.

Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle.

Sequential combination therapy of ovarian cancer with degradable N-(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates.

P304

30-42

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.COCIS.2017.07.003

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29276426

http://www.w3.org/2001/XMLSchema#string

P932

5739067

http://www.w3.org/2001/XMLSchema#string